PD-1 Blockade in Chinese versus Western Patients with Melanoma. uri icon

Overview

abstract

  • In this trial of programmed cell death-1 (PD-1) blockade with toripalimab in previously treated Chinese patients with melanoma, unique histologic and molecular features may explain why the objective response rate is lower than those defined in Western populations. This work suggests future avenues for investigating mechanisms of melanoma formation and resistance to PD-1 blockade.See related article by Tang et al., p. 4250.

publication date

  • June 2, 2020

Research

keywords

  • Melanoma
  • Programmed Cell Death 1 Receptor

Identity

PubMed Central ID

  • PMC7442612

Scopus Document Identifier

  • 85088141734

Digital Object Identifier (DOI)

  • 10.1016/j.ejca.2017.07.022

PubMed ID

  • 32487680

Additional Document Info

volume

  • 26

issue

  • 16